The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Another TIGIT bites the dust
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
AACR 2025 – Merck's head and neck headscratcher
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
Head and neck cancer is next for evorpacept
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
